Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece

Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece have?

Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece has 10 citations in the OpenAlex counts ScholarIQ stores.

When was Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece published?

Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece has 2020 year in the ScholarIQ index.

What is the open-access status of Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece?

Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece has closed oa status in the ScholarIQ index.

What is the DOI of Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece?

The DOI for Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece is on the source record.

What is the PMID of Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece?

The PMID for Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece is on the source record.

What is the OpenAlex record for Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece?

The OpenAlex for Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece is on the source record.